In vitro CYP450 enzyme down-regulation by GLP-1/glucagon co-agonist does not translate to observed drug-drug interactions in the clinic

Carolina Säll; Lene Alifrangis; Kirsten Dahl; Martin Haljeta Friedrichsen; Sune Boris Nygård; Kim Kristensen

doi:10.1124/dmd.122.000865

OtherArticle

In vitro CYP450 enzyme down-regulation by GLP-1/glucagon co-agonist does not translate to observed drug-drug interactions in the clinic

Carolina Säll, Lene Alifrangis, Kirsten Dahl, Martin Haljeta Friedrichsen, Sune Boris Nygård and Kim Kristensen

Drug Metabolism and Disposition June 9, 2022, DMD-AR-2022-000865; DOI: https://doi.org/10.1124/dmd.122.000865

Carolina Säll

1Novo Nordisk A/S, Denmark

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: cxls@novonordisk.com

Lene Alifrangis

1Novo Nordisk A/S, Denmark

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Kirsten Dahl

1Novo Nordisk A/S, Denmark

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Martin Haljeta Friedrichsen

1Novo Nordisk A/S, Denmark

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Sune Boris Nygård

1Novo Nordisk A/S, Denmark

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Kim Kristensen

1Novo Nordisk A/S, Denmark

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
eLetters
PDF + SI
PDF

Submit a Response to This Article

Compose eLetter

Title *

Contents

More information about text formats

Plain text

No HTML tags allowed.
Web page addresses and e-mail addresses turn into links automatically.
Lines and paragraphs break automatically.

Author Information

Contributors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests? *

Yes

Please describe the competing interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.

PreviousNext

In this issue

Drug Metabolism and Disposition

Vol. 50, Issue 6

1 Jun 2022

Table of Contents
About the Cover
Index by author

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following In vitro CYP450 enzyme down-regulation by GLP-1/glucagon co-agonist does not translate to observed drug-drug interactions in the clinic

Message Subject (Your Name) has forwarded a page to you from Drug Metabolism & Disposition

Message Body (Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

OtherArticle